Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nicotinic Acetylcholine Receptor of α7 Subtype is Linked to Glioblastoma Cholinergic Heterogeneity.

Journal of molecular neuroscience : MN·2026
Same author

Full-size recombinant ORF1p-L1 and RT domain of ORF2p-L1: Protein expression, purification and characterization.

Biochimica et biophysica acta. Proteins and proteomics·2026
Same author

Impact of the <i>etr1-1</i> Mutation, Impairing Ethylene Sensitivity, on Hormonal Status and Growth of <i>Arabidopsis thaliana</i> Under Salinity Stress.

Cells·2025
Same author

Aging and Thymosin Alpha-1.

International journal of molecular sciences·2025
Same author

Exploring allosteric properties of mammalian ALOX15: octyl (<i>N</i>-(4-(benzofuran-2-yl)-2-methoxyphenyl)sulfamoyl)- and octyl (<i>N</i>-(4-(1<i>H</i>-indol-2-yl)-2-methoxyphenyl)sulfamoyl)carbamates as ALOX inhibitors.

RSC advances·2025
Same author

Relationship Between Noninvasive Doppler-Derived Coronary Flow Reserve Measured by Transthoracic Echocardiography and Angiography Thermodilution-Measured Coronary Flow Reserve and the Index of Microcirculatory Resistance in Patients with Non-Obstructive Coronary Arteries.

Biomedicines·2025

Related Experiment Video

Updated: Jun 20, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

[Statins in aortic stenosis].

Jadranka Dejanović1, Igor Ivanov

  • 1Institut za kardiovaskularne bolesti Vojvodine 21204 Sremska Kamenica, Institutski put. dejanovicd@nadlanu.com

Medicinski Pregled
|August 26, 2009
PubMed
Summary

Statins may not benefit patients with calcific aortic stenosis unless they also have coronary artery disease. Current evidence does not support statin use for slowing aortic stenosis progression.

Area of Science:

  • Cardiovascular Medicine
  • Inflammatory Diseases
  • Pharmacology

Context:

  • Calcific aortic valve disease (CAVD) shares inflammatory and lipid-driven pathways with atherosclerosis.
  • Aortic valve stenosis (AS) is linked to increased cardiovascular morbidity and mortality.

Purpose:

  • To evaluate the potential benefits of statins in managing aortic stenosis.
  • To determine if statins can slow the hemodynamic progression of AS.

Summary:

  • Statins are effective in atherosclerosis but their role in AS is uncertain.
  • Retrospective studies suggested benefits, but prospective trials like SALTIRE found no halt in AS progression with intensive lipid lowering.
  • Current evidence does not support recommending statin therapy for AS without concurrent coronary artery disease.

More Related Videos

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

Impact:

  • Clarifies the current lack of evidence for statin efficacy in aortic stenosis management.
  • Guides clinical practice regarding statin use in patients with AS.
  • Highlights the need for further research into AS pathogenesis and treatment.